Interferon inducible antiviral mxais inversely associated with prostate cancer and regulates cell cycle, invasion and docetaxel induced apoptosis

Prostate

Volumn 75, Issue 3, 2015, Pages 266-279

  Brown, Shanora G ^a   Knowell, Ashley E ^a   Hunt, Aisha ^b   Patel, Divya ^b   Bhosle, Sushma ^b   Chaudhary, Jaideep ^b  

^a SOUTH CAROLINA STATE UNIVERSITY   (United States)

^b CLARK ATLANTA UNIVERSITY   (United States)

Author keywords

Docetaxel; MxA; Prostate cancer

Indexed keywords

ANDROGEN; BICALUTAMIDE; COLLAGENASE 3; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DOCETAXEL; LIPOCORTIN 5; MYXOVIRUS RESISTANCE PROTEIN A; TUBULIN; MX1 PROTEIN, HUMAN; MYXOVIRUS RESISTANCE PROTEIN; TAXOID;

ANCHORAGE INDEPENDENT GROWTH; APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE ARREST; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; CELLULAR DISTRIBUTION; COLONY FORMATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DNA SYNTHESIS; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LNCAP CELL LINE; MALE; MTT ASSAY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROSTATE EPITHELIUM CELL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; CELL DIVISION; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATIC NEOPLASMS; TUMOR CELL LINE; TUMOR INVASION;

APOPTOSIS; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; HUMANS; MALE; MYXOVIRUS RESISTANCE PROTEINS; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; TAXOIDS; TUBULIN;

EID: 84920738334     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22912     Document Type: Article

References (45)

1. Aebi M, Fah J, Hurt N, Samuel CE, Thomis D, Bazzigher L, Pavlovic J, Haller O, Staeheli P. cDNA structures and regulation of two interferon-induced human Mx proteins. Mol Cell Biol 1989; 9 (11): 5062-5072.
2. Horisberger MA, Gunst MC. Interferon-induced proteins: Identification of Mx proteins in various mammalian species. Virology 1991; 180: 185-190.
3. Horisberger MA. Interferon-induced human protein MxA is a GTPase which binds transiently to cellular proteins. J Virol 1992; 66 (8): 4705-4709.
4. Ott TL, Yin J, Wiley AA, Kim HT, Gerami-Naini B, Spencer TE, Bartol FF, Burghardt RC, Bazer FW. Effects of the estrous cycle and early pregnancy on uterine expression of Mx protein in sheep (Ovis aries). Biol Reprod 1998; 59 (4): 784-794.
5. Racicot K, Ott T. The myxovirus resistance protein, MX1, interacts with tubulin beta in uterine glandular epithelial cells. Am J Reprod Immunol 2011; 65 (1): 44-53.
6. Accola MA, Huang B, Al Masri A, McNiven MA. The antiviral dynamin family member, MxA, tubulates lipids and localizes to the smooth endoplasmic reticulum. J Biol Chem 2002; 277 (24): 21829-21835.
7. Mushinski JF, Nguyen P, Stevens LM, Khanna C, Lee S, Chung EJ, Lee MJ, Kim YS, Linehan WM, Horisberger MA, Trepel JB. Inhibition of tumor cell motility by the interferoninducible GTPase MxA. J Biol Chem 2009; 284 (22): 15206-15214.
8. Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P, Berney D, Foster CS, Fletcher A, Gerald WL, Moller H, Reuter V, De Bono JS, Scardino P, Cuzick J, Cooper CS. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008; 27 (3): 253-263.
9. Shou J, Soriano R, Hayward SW, Cunha GR, Williams PM, Gao WQ. Expression profiling of a human cell line model of prostatic cancer reveals a direct involvement of interferon signaling in prostate tumor progression. Proc Natl Acad Sci USA 2002; 99 (5): 2830-2835.
10. Nagano K, Masters JR, Akpan A, Yang A, Corless S, Wood C, Hastie C, Zvelebil M, Cramer R, Naaby-Hansen S. Differential protein synthesis and expression levels in normal and neoplastic human prostate cells and their regulation by type I and II interferons. Oncogene 2004; 23 (9): 1693-1703.
11. SchulzWA, Alexa A, Jung V, Hader C, Hoffmann MJ, Yamanaka M, Fritzsche S, Wlazlinski A, Muller M, Lengauer T, Engers R, Florl AR, Wullich B, Rahnenfuhrer J. Factor interaction analysis for chromosome 8 and DNA methylation alterations highlights innate immune response suppression and cytoskeletal changes in prostate cancer. Mol Cancer 2007; 6: 14.
12. Sedelaar JP, Isaacs JT. Tissue culture media supplemented with 10% fetal calf serum contains a castrate level of testosterone. Prostate 2009; 69 (16): 1724-1729.
13. Sharma P, Chinaranagari S, Patel D, Carey J, Chaudhary J. Epigenetic inactivation of inhibitor of differentiation 4 (Id4) correlates with prostate cancer. Cancer Med 2012; 1 (2): 176-186.
14. Walker L, Millena AC, Strong N, Khan SA. Expression of TGFbeta3 and its effects on migratory and invasive behavior of prostate cancer cells: Involvement of PI3-kinase/AKT signaling pathway. Clin Exp Metastasis 2013; 30 (1): 13-23.
15. Di Bona D, Cippitelli M, Fionda C, Cammà C, Licata A, Santoni A, Craxì A. Oxidative stress inhibits IFN-a-induced antiviral gene expression by blocking the JAK-STAT pathway. J Hepatol 2006; 45 (2): 271-279.
16. Dunn GP, Sheehan KCF, Old LJ, Schreiber RD. IFN Unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. Cancer Res 2005; 65 (8): 3447-3453.
17. Sobel RE, Sadar MD. Cell lines used in prostate cancer research: A compendium of old and new lines-Part 1. J Urol 2005; 173 (2): 342-359.
18. Mirochnik Y, Veliceasa D, Williams L, Maxwell K, Yemelyanov A, Budunova I, Volpert OV. Androgen receptor drives cellular senescence. PLoS ONE 2012; 7 (3): e31052.
19. Muller M, Brenig B, Winnacker EL, Brem G. Transgenic pigs carrying cDNA copies encoding the murine Mx1 protein which confers resistance to influenza virus infection. Gene 1992; 121 (2): 263-270.
20. Pang ST, Flores-Morales A, Skoog L, Chuan YC, Nordstedt G, Pousette A. Regulation of matrix metalloproteinase 13 expression by androgen in prostate cancer. Oncol Rep 2004; 11 (6): 1187-1192.
21. Bhalla KN. Microtubule-targeted anticancer agents and apoptosis. Oncogene 2003; 22 (56): 9075-9086.
22. Diaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: Reversibility, ligand stoichiometry, and competition. Biochemistry 1993; 32 (11): 2747-2755.
23. Yvon A-MC, Wadsworth P, Jordan MA. Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell 1999; 10 (4): 947-959.
24. Chang B-D, Broude EV, Dokmanovic M, Zhu H, Ruth A, Xuan Y, Kandel ES, Lausch E, Christov K, Roninson IB. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res 1999; 59 (15): 3761-3767.
25. Glymph S, Mandal S, Knowell AE, Abebe F, Chaudhary J. The myxovirus resistance A (MxA) gene -88G>T single nucleotide polymorphism is associated with prostate cancer. Infect Genet Evol 2013; 16: 186-190.
26. Bettoun DJ, Scafonas A, Rutledge SJ, Hodor P, Chen O, Gambone C, Vogel R, McElwee-Witmer S, Bai C, Freedman L, Schmidt A. Interaction between the androgen receptor and RNase L mediates a cross-talk between the interferon and androgen signaling pathways. J Biol Chem 2005; 280 (47): 38898-38901.
27. Gil MP, Bohn E, O'Guin AK, Ramana CV, Levine B, Stark GR, Virgin HW, Schreiber RD. Biologic consequences of Stat1-independent IFN signaling. Proc Natl Acad Sci 2001; 98 (12): 6680-6685.
28. Basrawala Z, Alimirah F, Xin H, Mohideen N, Campbell SC, Flanigan RC, Choubey D. Androgen receptor levels are increased by interferons in human prostate stromal and epithelial cells. Oncogene 2006; 25 (19): 2812-2817.
29. Hobeika AC, Subramaniam PS, Johnson HM. IFNalpha induces the expression of the cyclin-dependent kinase inhibitor p21 in human prostate cancer cells. Oncogene 1997; 14 (10): 1165-1170.
30. Hobeika AC, Etienne W, Cruz PE, Subramaniam PS, Johnson HM. IFNgamma induction of p21WAF1 in prostate cancer cells: Role in cell cycle, alteration of phenotype and invasive potential. Int J Cancer 1998; 77 (1): 138-145.
31. Kominsky SL, Hobeika AC, Lake FA, Torres BA, Johnson HM. Down-regulation of neu/HER-2 by interferon-gamma in prostate cancer cells. Cancer Res 2000; 60 (14): 3904-3908.
32. Masamha CP, Benbrook DM. Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells. Cancer Res 2009; 69 (16): 6565-6572.
33. Yoshida T, Zhang Y, Rivera Rosado LA, Chen J, Khan T, Moon SY, Zhang B. Blockade of Rac1 activity induces G1 cell cycle arrest or apoptosis in breast cancer cells through downregulation of cyclin D1, survivin, and X-linked inhibitor of apoptosis protein. Mol Cancer Ther 2010; 9 (6): 1657-1668.
34. Sandor V, Senderowicz A, Mertins S, Sackett D, Sausville E, Blagosklonny MV, Bates SE. P21-dependent g (1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by thehistone deacetylase inhibitor FR901228. Br J Cancer 2000; 83 (6): 817-825.
35. Hamdi N, El-Akel W, El-Serafy M, Esmat G, Sarrazin C, Abdelaziz AI. Transcriptional response of MxA, PKR and SOCS3 to interferon-based therapy in HCV genotype 4-infected patients and contribution of p53 to host antiviral response. Intervirology 2012; 55 (3): 210-218.
36. Dharel N, Kato N, Muroyama R, Taniguchi H, Otsuka M, Wang Y, Jazag A, Shao RX, Chang JH, Adler MK, Kawabe T, Omata M. Potential contribution of tumor suppressor p53 in the host defense against hepatitis C virus. Hepatology 2008; 47 (4): 1136-1149.
37. Muñoz-Fontela C, Macip S, Martínez-Sobrido L, Brown L, Ashour J, García-Sastre A, Lee SW, Aaronson SA. Transcriptional role of p53 in interferon-mediated antiviral immunity. J Exp Med 2008; 205 (8): 1929-1938.
38. Zemskova M, Lilly MB, Lin Y-W, Song JH, Kraft AS. p53-Dependent induction of prostate cancer cell senescence by the PIM1 protein kinase. Mol Cancer Res 2010; 8 (8): 1126-1141.
39. Li Y, Jenkins CW, Nichols MA, Xiong Y. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene 1994; 9 (8): 2261-2268.
40. Pellegrini F, Budman DR. Review: Tubulin function, action of antitubulin drugs, and new drug development. Cancer Invest 2005; 23 (3): 264-273.
41. Singh P, Rathinasamy K, Mohan R, Panda D. Microtubule assembly dynamics: An attractive target for anticancer drugs. IUBMB Life 2008; 60 (6): 368-375.
42. Brouty-Boye D, Zetter BR. Inhibition of cell motility by interferon. Science 1980; 208 (4443): 516-518.
43. Tan TW, Yang WH, Lin YT, Hsu SF, Li TM, Kao ST, Chen WC, Fong YC, Tang CH. Cyr61 increases migration and MMP-13 expression via alphavbeta3 integrin, FAK, ERK and AP-1-dependent pathway in human chondrosarcoma cells. Carcinogenesis 2009; 30 (2): 258-268.
44. van Haelst-Pisani CM, Richardson RL, Su J, Buckner JC, Hahn RG, Frytak S, Kvols LK, Burch PA. A phase II study of recombinant human alpha-interferon in advanced hormonerefractory prostate cancer. Cancer 1992; 70 (9): 2310-2312.
45. Li YF, Wang QZ, Zhang TT, Li L, Wang JP, Ding GF, He DL. Low dose of interferon-alpha improves the clinical outcomes of docetaxel in patients with castration-resistant prostate cancer: A pilot study. Oncol Lett 2014; 7 (1): 125-130.